Today is World Malaria Day. The day is observed every year to create awareness among the people about this vector borne disease. Within the next four years, six nations in … continue reading
More than half the world’s population is at risk from diseases such as malaria, dengue, leishmaniasis, Lyme disease, schistosomiasis, and yellow fever, carried by mosquitoes, flies, ticks, water snails and … continue reading
Scientists have discovered a new molecules that can kill the malaria parasite, paving way for effective treatment for the disease. Using ultra sophisticated computerised modelling tools, researchers were successful in … continue reading
Recognizing the role of scientific inputs for accessible and affordable healthcare programmes, Prime Minister Dr Manmohan Singh said that government has established a new department for Health Education and Research. … continue reading
Travel medicine or emporiatrics is the branch of medicine that deals with the prevention and management of health problems of international travelers. Globalization facilitates the spread of disease and increases … continue reading
Nutrition is the pre-requisite of beauty. There is peaceful co-existence of Allopathy with Ayurveda, Yoga, Siddha and Sowa-Rigpa in our country, Union Minister of Health & Family Welfare, Shri Ghulam … continue reading
The United Nations-backed Global Fund to Fight AIDS, Tuberculosis and Malaria approved $1.1 billion of new grants to be handed out over the next two years and agreed to allocate another $130 million to five projects it had already started supporting.
Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium attract and then destroy protective human white blood cells—a key process ensuring that S. aureus survives and causes severe disease, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The first study to test GlaxoSmithKline’s (GSK) investigational RTS,S/AS02 malaria vaccine in African infants serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and clinical illness due to malaria, according to a paper published today online in The Lancet.
MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR™. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus.